Exenatide- Qrono

Drug Profile

Exenatide- Qrono

Alternative Names: Exenatide Qx; QR 108

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Qrono
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Endocrine disorders

Highest Development Phases

  • Preclinical Endocrine disorders

Most Recent Events

  • 03 Aug 2017 Exenatide- Qrono is available for licensing as of 03 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)
  • 03 Aug 2017 Early research in Endocrine disorders in USA (Parenteral) before August 2017 (Qrono pipeline, August 2017)
  • 03 Aug 2017 Preclinical trials in Endocrine disorders in USA (Parenteral) (Qrono pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top